Jazz Pharmaceuticals Stock Price, News & Analysis (NASDAQ:JAZZ) $114.49 -3.05 (-2.59%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$111.25▼$117.2150-Day Range$114.49▼$136.0052-Week Range$111.25▼$160.96Volume1.52 million shsAverage Volume715,410 shsMarket Capitalization$7.21 billionP/E Ratio130.10Dividend YieldN/APrice Target$194.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Jazz Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside70.2% Upside$194.86 Price TargetShort InterestHealthy4.08% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.33Based on 7 Articles This WeekInsider TradingSelling Shares$236,748 Sold Last QuarterProj. Earnings Growth13.50%From $15.41 to $17.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector116th out of 949 stocksPharmaceutical Preparations Industry39th out of 440 stocks 3.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $194.86, Jazz Pharmaceuticals has a forecasted upside of 70.2% from its current price of $114.49.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.08% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 6.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 1.8 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest17 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $236,748.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions88.15% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 13.50% in the coming year, from $15.41 to $17.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 130.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 114.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 130.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 99.68.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Stock News HeadlinesNovember 28, 2023 | msn.comUBS Downgrades Jazz Pharmaceuticals (JAZZ)November 28, 2023 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded by UBS Group to "Neutral"November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 27, 2023 | uk.investing.comTeva Pharma 'uniquely positioned,' Jazz Pharmaceuticals set-up balanced - UBSNovember 27, 2023 | insidermonkey.com5 Best Upside Stocks To Buy NowNovember 14, 2023 | thetimes.co.ukJazz global licensing deal swings IP Group sharesNovember 14, 2023 | markets.businessinsider.comIP Group: Autifony Signs Up To $770 Mln Worth Global Licencing Deal With Jazz PharmaNovember 14, 2023 | msn.comJazz Pharma enters collaboration to develop neurological drugsNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | finance.yahoo.comAutifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological DisordersNovember 10, 2023 | finance.yahoo.comIs Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) ROE Of 2.3% Concerning?November 9, 2023 | finance.yahoo.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finance.yahoo.comCompared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key MetricsNovember 8, 2023 | seekingalpha.comJazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call PresentationNovember 8, 2023 | finanznachrichten.deJazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceNovember 8, 2023 | finance.yahoo.comJazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue GuidanceNovember 8, 2023 | finance.yahoo.comJazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceNovember 8, 2023 | benzinga.comEpilepsy Drugs Market Size Worth $10.70 Billion, Globally, by 2030 - Exclusive Report by The Insight PartnersNovember 7, 2023 | markets.businessinsider.comZymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comUnlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key MetricsNovember 7, 2023 | markets.businessinsider.comJazz Pharma, MD Anderson Collaborate To Evaluate Zanidatamab In HER2-Expressing CancersNovember 7, 2023 | finance.yahoo.comJazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing CancersNovember 1, 2023 | finanznachrichten.deJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming November Investor ConferencesOctober 26, 2023 | benzinga.comAdvancing Neuroendocrine Tumor Treatment Pipeline: Comprehensive Insights into Clinical Trials by 55+ Key Companies by DelveInsightOctober 25, 2023 | finance.yahoo.comJazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023October 23, 2023 | finance.yahoo.comJazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023October 21, 2023 | msn.comJazz Pharma (NASDAQ:JAZZ) Evaluating Strategic OptionsSee More Headlines Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$194.86 High Stock Price Target$225.00 Low Stock Price Target$135.00 Potential Upside/Downside+70.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio130.10 Forward P/E Ratio7.43 P/E Growth0.94Net Income$-224,060,000.00 Net Margins2.11% Pretax Margin-2.73% Return on Equity22.23% Return on Assets6.73% Debt Debt-to-Equity Ratio1.46 Current Ratio2.06 Quick Ratio1.67 Sales & Book Value Annual Sales$3.66 billion Price / Sales1.97 Cash Flow$21.52 per share Price / Cash Flow5.32 Book Value$55.42 per share Price / Book2.07Miscellaneous Outstanding Shares62,960,000Free Float60,187,000Market Cap$7.21 billion OptionableOptionable Beta0.73 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Bruce C. Cozadd (Age 59)Co-Founder, Chairman & CEO Comp: $2.45MMs. Renee D. Gala (Age 51)President & COO Comp: $1.13MMr. Daniel N. Swisher Jr. (Age 60)Non-Executive Employee Comp: $1.47MDr. Robert Iannone M.D. (Age 56)Executive VP and Global Head of Research & Development Comp: $1.08MMs. Kim Sablich M.B.A. (Age 54)Executive VP & GM of US Comp: $997.91kMs. Patricia Carr (Age 52)Senior VP, CFO, & Chief Accounting Officer Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsMs. Neena M. Patil J.D. (Age 47)Executive VP & Chief Legal Officer Comp: $331.61kDr. George Christopher Eliades Ph.D. (Age 52)Senior VP of Corporate Development & Chief Transformation Officer Ms. Heidi Manna (Age 52)Senior VP & Chief People Officer More ExecutivesKey CompetitorsPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVKaruna TherapeuticsNASDAQ:KRTXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 24,602 shares on 11/24/2023Ownership: 0.207%Graham Capital Management L.P.Bought 9,419 shares on 11/22/2023Ownership: 0.015%Braun Stacey Associates Inc.Sold 10,563 shares on 11/21/2023Ownership: 0.175%Walleye Trading LLCSold 2,600 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCBought 2,200 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions JAZZ Stock Analysis - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price target for 2024? 8 equities research analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $135.00 to $225.00. On average, they predict the company's stock price to reach $194.86 in the next year. This suggests a possible upside of 70.2% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2023? Jazz Pharmaceuticals' stock was trading at $159.31 at the start of the year. Since then, JAZZ stock has decreased by 28.1% and is now trading at $114.49. View the best growth stocks for 2023 here. Are investors shorting Jazz Pharmaceuticals? Jazz Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, a decline of 6.2% from the October 31st total of 2,740,000 shares. Based on an average daily trading volume, of 644,000 shares, the short-interest ratio is presently 4.0 days. View Jazz Pharmaceuticals' Short Interest. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a net margin of 2.11% and a trailing twelve-month return on equity of 22.23%. During the same period in the previous year, the company posted $3.86 EPS. What ETFs hold Jazz Pharmaceuticals' stock? ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), Amplify Seymour Cannabis ETF (CNBS), AdvisorShares Pure Cannabis ETF (YOLO), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Pharmaceutical ETF (PPH), Invesco Pharmaceuticals ETF (PJP), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $18.15-$19.00 for the period, compared to the consensus earnings per share estimate of $18.66. The company issued revenue guidance of $3.75-$3.875 billion, compared to the consensus revenue estimate of $3.83 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (3.76%), JPMorgan Chase & Co. (2.26%), FMR LLC (2.12%), Ameriprise Financial Inc. (2.06%), Polaris Capital Management LLC (1.97%) and Morgan Stanley (1.30%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More This page (NASDAQ:JAZZ) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.